Vera Therapeutics (VERA) News Today $45.75 -0.15 (-0.33%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period GSA Capital Partners LLP Trims Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)GSA Capital Partners LLP cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 62.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,113 shares of the company's stock after selling 20November 20 at 3:21 AM | marketbeat.comFirst Turn Management LLC Buys 113,550 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)First Turn Management LLC boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 53.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 326,494 shares of the company's stock after purchasing anNovember 19 at 6:08 AM | marketbeat.comVera Therapeutics appoints Jason Carter as Chief Legal OfficerNovember 18 at 7:27 PM | markets.businessinsider.comPolycythemia Vera Market Size in the 7MM is ~USD 1,800 million in 2023, estimated DelveInsightNovember 18 at 7:27 PM | theglobeandmail.comVera Therapeutics Appoints Jason S. Carter as Chief Legal OfficerNovember 18 at 7:27 PM | finance.yahoo.comVera Therapeutics (NASDAQ:VERA) Hits New 52-Week High - Time to Buy?Vera Therapeutics (NASDAQ:VERA) Hits New 52-Week High - Time to Buy?November 13, 2024 | marketbeat.comVera Therapeutics partners with University of Michigan on NEPTUNE match projectNovember 13, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by BrokeragesNovember 12, 2024 | americanbankingnews.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.comVera Therapeutics Advances in Autoimmune TreatmentNovember 9, 2024 | markets.businessinsider.comVera Therapeutics to Participate at Upcoming Investor ConferencesNovember 8, 2024 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPSVera Therapeutics (NASDAQ:VERA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21).November 8, 2024 | marketbeat.comWedbush Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceWedbush increased their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research report on Friday.November 8, 2024 | marketbeat.comVera Therapeutics to Participate at Upcoming Investor ConferencesNovember 8, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comVera Therapeutics: Strong Buy Rating Backed by Financial Stability and Promising Atacicept DataNovember 7, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been given an average recommendation of "Buy" by the ten research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have aNovember 7, 2024 | marketbeat.comJ.P. Morgan Sticks to Its Buy Rating for Vera Therapeutics (VERA)November 6, 2024 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Given New $75.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a report on Tuesday.November 5, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Up 7.3% - What's Next?Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.3% - Should You Buy?November 1, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Sells $720,450.00 in StockOctober 31, 2024 | insidertrades.comVera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase - Here's What HappenedVera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase - Time to Buy?October 30, 2024 | marketbeat.comVera Therapeutics 7.14M share Secondary priced at $42.00October 30, 2024 | markets.businessinsider.comVera Therapeutics prices $300M offering at $42 per shareOctober 30, 2024 | msn.comVera Therapeutics Announces Pricing of Public Offering of Class A Common StockOctober 29, 2024 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comVera Therapeutics Breaks Out On Promising Results For Kidney DrugOctober 29, 2024 | msn.comVera Therapeutics price target raised to $64 from $56 at GuggenheimOctober 29, 2024 | finance.yahoo.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Time to Sell?Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?October 29, 2024 | marketbeat.comVera Therapeutics Advances Atacicept with Promising Trial ResultsOctober 28, 2024 | markets.businessinsider.comVera Therapeutics announces $300M offering of Class A common stockOctober 28, 2024 | markets.businessinsider.comScotiabank Sticks to Its Buy Rating for Vera Therapeutics (VERA)October 28, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Vera Therapeutics (VERA)October 28, 2024 | markets.businessinsider.comVera Therapeutics Announces Proposed Public Offering of Class A Common StockOctober 28, 2024 | globenewswire.comVera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at GuggenheimGuggenheim raised their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research report on Monday.October 28, 2024 | marketbeat.comVera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease StudyOctober 28, 2024 | marketwatch.comVera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two YearsOctober 28, 2024 | benzinga.comVera Therapeutics Eyes Breakout On Promising Results For Kidney DrugOctober 28, 2024 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Time to Buy?Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's WhyOctober 28, 2024 | marketbeat.comVera Therapeutics Announces Long-Term Kidney Function Stabilization With Atacicept In IgAN TrialOctober 28, 2024 | markets.businessinsider.comPromising Clinical Data and Strong Financials Justify Buy Rating for Vera Therapeutics Amid Atacicept’s Potential in IgANOctober 28, 2024 | markets.businessinsider.comMarshall Fordyce Sells 19,375 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockOctober 27, 2024 | insidertrades.comVera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024October 26, 2024 | globenewswire.comVera Therapeutics: Promising Growth Potential with Atacicept’s Positive Data and Strategic PositioningOctober 23, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Vera Therapeutics (VERA)October 23, 2024 | markets.businessinsider.com56,050 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Purchased by Eastern BankEastern Bank purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 56,050 shares of the company's stock, valued at approximately $2,477,000. EasOctober 23, 2024 | marketbeat.comScotiabank Initiates Coverage of Vera Therapeutics (VERA) with Sector Outperform RecommendationOctober 17, 2024 | msn.comScotiabank Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)Scotiabank began coverage on Vera Therapeutics in a research report on Wednesday. They set a "sector outperform" rating for the company.October 16, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendOctober 13, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 15,625 SharesOctober 12, 2024 | insidertrades.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.530.46▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼55▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vaxcyte News Today Catalent News Today Sarepta Therapeutics News Today Revolution Medicines News Today Qiagen News Today Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Legend Biotech News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERA Stock Alerts